it has been found that a combination of vitamin d3 ( cholecalciferol ) and 25 - oh d3 ( calcifediol ), for use as a medicament , nutraceutical or food for bone health in a human has advantages over the administration of either vitamin d3 alone or 25 - hydroxyvitamin d3 alone . the human may be any age , including children and juveniles , starting from birth to adulthood , and from 18 years to 80 years of age , or more than 80 years of age . in a first aspect , one or more pharmaceutical , nutraceutical or food compositions suitable for human use are provided to administer both vitamin d3 and 25 - oh d3 and a pharmaceutically acceptable carrier and thereby maintain bone health and / or treat and / or prevent osteoporosis . this invention is also drawn to a human pharmaceutical composition for treatment of bone diseases and / or the maintenance of bone health , wherein the active ingredients consist essentially of a combination of vitamin d and 25 - oh d3 . in another aspect , a kit is provided which is comprised of multiple , separate dosages of the composition of vitamin d3 and 25 - oh d3 . they may be enclosed in a container : e . g ., bottle , blister pack , or vial rack . optionally , one or more other osteoporosis medicaments such as bisphosphonate compounds may be enclosed in the container . further , instructions for administering the composition as a dosage to a human are provided within the kit . in another aspect , a method of administering at least vitamin d3 and 25 - hydroxy vitamin d3 to a human is provided to treat and / or prevent osteoporosis . they may be administered once per day , once per week , or once per month . vitamin d3 and 25 - oh d3 can be co - administered with or without other osteoporosis medicaments , in combination or via separate formulations and not necessarily at the same time . “ other osteoporosis medicaments ” as used herein refers to other compounds which may be administered to relieve , ameliorate , prevent , delay onset or the like of osteoporosis . examples include : bisphosphonates , monoclonal antibodies , calcium forms , estrogens , phytoestrogens , and the like . another aspect of this invention is a bone health promoting food , functional food , food supplement or nutraceutical suitable for human consumption containing 25 - oh d3 , and preferably a combination of vitamin d and 25 - oh d3 . in another embodiment , the 25 - oh d3 , alone or in combination with vitamin d is the bone health promoting active ingredient in a food , functional food , food supplement or nutraceutical suitable for human consumption . the dosages of the 25 - oh and / or d3 may be the same as those present in the pharmaceutical product , but preferably will tend towards the lower ranges . the food supplements and nutraceuticals may be in the form of tablets , capsules or other convenient dosage forms . the food may be a beverage or food , and if desired , may also contain other nutritionally effective compounds such as other vitamins , minerals , and the like . “ bone health ” is meant to be a broad term . maintainance of bone health is meant to encompass prevention of osteoporosis / osteopenia , rickets / osteomalasia , maintaining normal bone resorption / formation and regeneration events , maintaining normal ca + metabolism and preventing abnormal mobilization , and increasing peak bone mass . “ vitamin d ” means either vitamin d3 ( cholecalciferol ) and / or vitamin d2 ( ergocalciferol ). humans are unable to make vitamin d2 ( ergocalciferol ), but are able to use it as a source of vitamin d . vitamin d2 can be synthesized by various plants and is often used in vitamin d in supplements as an equivalent to vitamin d . “ vitamin d metabolite ” means any metabolite of vitamin d other than 25 - hydroxy vitamin d3 . “ 25 - oh d ” refers to the 25 - hydroxylated metabolite of either vitamin d2 or vitamin d3 which is the major circulating form found in plasma . “ prevent ” is meant to include amelioration of the disease , lessening of the severity of the symptoms , early intervention , and lengthening the duration of onset of the disease , and is not intended to be limited to a situation where the patient is no longer able to contract the disease nor experience any symptoms . “ bisphosphonates ” include alendronate , clodronate , etidronate , ibandronate , olpadronate , minodronate , pamidronate , risedronate , tiludronate , and zoledronate . “ other osteoporosis medicaments ” as used herein refers to other compounds which may be administered to relieve , ameliorate , prevent , delay onset or the like of osteoporosis . examples include : bisphosphonates , monoclonal antibodies , calcium forms , estrogens , phytoestrogens and the like . vitamin d deficiency is a leading contributor to bone health problems . vitamin d deficiency / insufficiency is an especially prevalent condition in the elderly population and those who suffer chronic immobility regardless of age . furthermore infants , toddlers , children , adolescences and young adults can suffer from hidden vitamin d deficiency . this may be due to the general lack of exposure to sunlight , a lessened ability of the body to manufacture vitamin d or metabolize it efficiently , or a number of other causes such as use of sunblockers whenever outside . thus one aspect of this invention is the use of the combination of vitamin d and 25 - oh d3 to promote bone health in an elderly population . as used throughout , the term “ elderly ” is meant to encompass those individuals who are over 65 years of age , preferably over 70 , and even over 80 . in another embodiment , this combination of 25 - oh d3 and vitamin d is suitable for maintaining bone health in people who are at risk of developing conditions characterized by vitamin d deficiency or insufficiency . this would include especially all adults , including post - menopausal women ( i . e . about age 45 and older ) and men who are about age 45 and older . it is especially suitable for maintaining bone health in individuals who do not receive a great deal of natural sunlight exposure , such as for people who traditionally wear long clothing , do not go out of doors regularly , or who use sunscreens when they are exposed to sunlight , or live in geographical areas significantly north or south of the equator , where sunlight is less intense . in another embodiment , the combination of 25 - oh d3 and vitamin d is suitable for improving bone health in children and young adults who are in the modeling phase of building bones . this is particularly a concern if they are at risk of vitamin d deficiency or insufficiency before reaching peak bone mass . it is especially suitable for improving bone health in individuals before peak bone mass who do not receive a great deal of natural sunlight exposure , such as for the population who traditionally wear long clothing , do not go outdoors regularly , who use sunscreens when they are exposed to sunlight , or live in geographical areas significantly north or south of the equator , where sunlight is less intense . thus another aspect of this invention is the use of the combination of 25 - oh d3 and vitamin d3 to increase peak bone mass in individuals who are in the modeling phase of building bone . another aspect of this invention is a method of maintaining bone health in persons with a malabsorption syndrome ( e . g ., affected by celiac disease , sprue , or short bowel syndrome ) by administering the combination of vitamin d and 25 - oh d3 . another aspect of this invention is a method of maintaining bone health in persons with impaired liver function , wherein the person cannot efficiently process vitamin d into 25 - hydroxyvitamin d by providing the person with a combination of vitamin d and 25 - hydroxyvitamin d3 . vitamin d3 and 25 - oh d3 may be obtained from any source , and a composition thereof may be prepared using convenient technology . in general , crystals of vitamin d3 , 25 - oh d3 , or both ( separately or together ) are dissolved in an oil with heating and agitation . preferably , the oil is transferred into a vessel and heated . thereafter , vitamin d3 , 25 - oh d3 , or both are added to the vessel , while maintaining the temperature of the oil or increasing it over time . the composition is agitated to dissolve the crystals of vitamin d3 , 25 - oh d3 , or both . prior to addition to the oil , the crystals may be reduced in size by milling and / or sieving , to enhance dissolving . the composition may be agitated by stirring , vessel rotation , mixing , homogenization , recirculation , or ultrasonication . preferably , the oil may be heated in the vessel to a temperature from about 80 ° c . to about 85 ° c ., sized crystals are introduced into the vessel , and the contents are stirred to dissolve the crystals into the oil . the “ oil ” may be any edible oil , lipid , or fat : e . g ., babassu oil , coconut oil , cohune oil , murumyru tallow , palm kernel oil , or tucum oil . the oil may be natural , synthetic , semisynthetic , or any combination thereof . natural oil may be derived from any source ( e . g ., animal , plant , fungal , marine ); synthetic or semisynthetic oil may be produced by convenient technology . preferably , the oil is a mixture of plant medium chain triglycerides , mainly caprylic and capric acids . the composition may optionally contain one or more other suitable ingredients such as , for example , antioxidants , preservatives , dissolution agents , surfactants , ph adjusting agents or buffers , humectants , and any combination thereof . the foregoing are examples of pharmaceutically acceptable carriers . suitable antioxidants include tocopherol , mixed tocopherols , tocopherols from natural or synthetic sources , butylated hydroxy toluene ( bht ), butylated hydroxy anisole ( bha ), natural antioxidants like rosemary extract , propyl galate , and any others used in the manufacture of pharmaceuticals for humans . preferably , the antioxidant is tocopherol . suitable preservatives include methyl paraben , propyl paraben , potassium sorbate , sodium benzoate , benzoic acid , and any combination thereof . suitable dissolution agents include inorganic or organic solvents : e . g ., alcohols , chlorinated hydrocarbons , and any combination thereof . suitable surfactants may be anionic , cationic , or nonionic : e . g ., ascorbyl palmitate , polysorbates , polyethylene glycols , and any combination thereof . suitable ph adjusting agents or buffers include citric acid - sodium citrate , phosphoric acid - sodium phosphate , acetic acid - sodium acetate , and any combination thereof . suitable humectants include glycerol , sorbitol , polyethylene glycol , propylene glycol , and any combination thereof . once formed , the oil composition may be incorporated in various other useful compositions , some of which are discussed below . for example , emulsions may be formed , which may be optionally encapsulated or spray dried . a variety of emulsions may be prepared by combining the nonaqueous compositions described above with an aqueous composition . the emulsion may be of any type . suitable emulsions include oil - in - water emulsions , water - in - oil emulsions , anhydrous emulsions , solid emulsions , and microemulsions . the emulsions may be prepared by any convenient technology . the emulsion contains an aqueous composition and a nonaqueous ( e . g ., oil ) composition , wherein the latter comprises vitamin d3 , 25 - oh d3 , or both ( separately or together ) dissolved in an oil in an amount of between about 3 % and about 50 % by weight based on the total weight of the oil composition . as used herein , “ aqueous composition ” and “ aqueous phase ” are used interchangeably . generally , the emulsion may contain from about 20 % to about 95 % of an aqueous composition , and from about 5 % to about 80 % of a nonaqueous composition . preferably , however , the emulsion contains from about 85 % to about 95 % ( vol / vol ) of an aqueous composition , and from about 5 % to about 15 % ( vol / vol ) of a nonaqueous composition . conveniently , the nonaqueous composition may be dispersed as droplets in the aqueous composition . for example , the droplets may have a mean diameter of less than about 500 nm in the aqueous composition . conveniently , the droplets have a mean diameter of between about 100 nm and about 200 nm . in a particularly advantageous embodiment , the emulsion contains an encapsulating agent , which facilitates encapsulating the oil composition upon further processing of the emulsion ( e . g ., by spray drying ). the encapsulating agent may be any edible substance capable of encapsulating the oil composition . preferably , the encapsulation agent is predominantly a colloidal material . such materials include starches , proteins from animal sources ( including gelatins ), proteins from plant sources , casein , pectin , alginate , agar , maltodextrins , lignin sulfonates , cellulose derivatives , sugars , saccharides , sorbitols , gums , and any combination thereof . suitable starches include : plant starches ( e . g ., capsul ® or hi - cap ® from national starch & amp ; chemical corp ., new york , n . y . ), other modified food starches , and any combination thereof . preferably , the starch is capsul ® modified plant starch . suitable proteins from animal sources include : gelatins ( e . g ., bovine gelatins , porcine gelatins ( type a or b ) with different bloom numbers , fish gelatins ), skim milk protein , caseinate , and any combination thereof . preferably , the animal protein is a gelatin . suitable proteins from plant sources include : potato protein ( e . g ., alburex ® from roquette preres societe anonyme , lestrem , france ), pea protein , soy protein , and any combination thereof . preferably , the plant protein is alburex ® potato protein . suitable maltodextrins with a different dextrose equivalent include : maltodextrin 5 , maltodextrin 10 , maltodextrin 15 , maltodextrin 20 , maltodextrin 25 , and any combination thereof . preferably , the maltodextrin is maltodextrin 15 . suitable cellulose derivatives include : ethyl cellulose , methylethyl cellulose , hydroxypropyl cellulose , hydroxypropylmethyl cellulose , carboxymethylcellulose , and any combination thereof . suitable saccharides include lactose , sucrose , or any combination thereof . preferably , the saccharide is sucrose . suitable gums include : acacia , locust bean , carragean , and any combination thereof . preferably , the gum is gum acacia . when the emulsion contains an encapsulating agent , the encapsulating agent may be dispersed in water by any convenient technology to form an aqueous phase . the aqueous phase may be a solution or a mixture depending on the properties of the components selected . the selected components may be dispersed by any convenient technology including : homogenizing , mixing , emulsifying , recirculating , static mixing , ultrasonication , stirring , heating , or any combination thereof . the viscosity of the resulting aqueous phase may then be adjusted , as desired , by the addition of water . the aqueous composition of the emulsion may optionally contain any other suitable material including but not limited to , those discussed above in reference to the nonaqueous composition . preferably , the aqueous composition may include , an encapsulating agent , a film - forming agent , a plasticizer , a preservative , an antioxidant , or any combination thereof . suitable preservatives include methyl paraben , propyl paraben , sorbic acid , potassium sorbate , sodium benzoate , and any combination thereof . suitable antioxidants include sodium ascorbate , ascorbic acid , citric acid , and any combination thereof . preferably , the aqueous phase contains a modified food starch , such as octenyl succinyl starch ( capsul ®), maltodextrin , and sodium ascorbate . another preferred aqueous phase contains potato protein ( alburex ®), maltodextrin 20 , and sodium ascorbate . the selected components may be dissolved in water by any convenient technology , preferably stirring . the mixture is preferably homogenized until it is uniform and lump free . preferably , the homogenization is carried out at a temperature between about 50 ° c . and about 75 ° c . the final viscosity of the resulting aqueous phase may then be adjusted to the desired viscosity , preferably about 250 cp to about 450 cp , more preferably about 300 cp to about 400 cp , even more preferably about 385 cp . the emulsion may be formed by emulsifying the nonaqueous composition and the aqueous phase by any means , including homogenization , rotor - stator shear , high pressure shear and cavitation , high speed “ cowles ” or shear agitation , and any combination thereof . the volume and viscosity of the emulsion may preferably be adjusted by the addition of water after emulsification . preferably , the nonaqueous and aqueous compositions are emulsified by homogenization . preferably , the emulsion should not contain any mineral , transition metal , or peroxide . as noted above , the emulsion may be incorporated or employed in producing other useful compositions , especially encapsulated oils , e . g ., spray - dried powders . generally , the encapsulated oil comprises an oil composition and an encapsulation agent encapsulating the oil composition , wherein the oil composition contains vitamin d3 , 25 - oh d3 , or both dissolved in the oil in an amount between about 3 % and about 50 % by weight based on the total weight of the oil composition . the encapsulated oil may be produced by any convenient technology : e . g ., drying an emulsion described above by any conventional technology , including spray drying , freeze drying , fluid bed drying , tray drying , adsorption , and any combination thereof . preferably , the encapsulated oil is produced by spray drying an emulsion having an aqueous phase above containing an encapsulation agent ; spray drying parameters are dictated by the physical characteristics desired in the final encapsulated oil . such physical parameters include particle size , powder shape and flow , and water content . preferably , the oil is in an amount less than about 30 %, less than about 20 %, less than about 10 %, or less than about 3 % by weight based on the total weight of the encapsulated oil . the encapsulated oil should have good flowability and the vitamin d3 and / or 25 - oh d3 should be distributed homogeneously throughout the composition . conveniently , the encapsulated oil is a powder . any other suitable additive may be added to the encapsulated oil . one such additive may be a flow agent such as silicon dioxide , to increase the flowability of the encapsulated oil . daily . a composition according to this invention where the two active ingredients are to be administered separately , contains vitamin d or 25 - oh d3 in an amount from about 1 μg to about 50 μg , preferably about 5 μg and 25 μg . alternatively , a single daily dosage having both vitamin d and 25 - oh d3 contains each active ingredient in an amount from about 1 μg to about 50 μg , preferably about 5 μg and 25 μg . the dosage ratio of vitamin d to 25 - oh d3 may be from about 50 : 1 to about 1 : 50 , more preferably from about 25 : 1 to about 1 : 25 , and even more preferably from about 6 : 1 to about 1 : 6 . multiple , separate dosages may be packaged in a single kit ( or container ). for example , the kit may be comprised of thirty separate daily dosages of both actives separately ( i . e . 60 separate dosages ), or combined ( i . e . 30 dosages containing both active ingredients ). instructions for administering the dosages to a human may be included in the kit . weekly . a single weekly dosage contains vitamin d or 25 - oh d3 in an amount from about 7 μg to about 350 μg , and preferably from about 35 to 175 μg . alternatively , a single weekly dosage may contain both vitamin d and 25 - oh d3 each in an amount from about 7 μg to about 350 μg , and preferably from about 35 to 175 μg . the dosage ratio of vitamin d to 25 - oh d3 may be from about 50 : 1 to about 1 : 50 , more preferably from about 25 : 1 to about 1 : 25 , and even more preferably from about 6 : 1 to about 1 : 6 . monthly . a single monthly dosage contains vitamin d or 25 - oh d3 in an amount from 30 μg to about 1500 μg , preferably about 75 μg to about 500 μg . alternatively , a single monthly dosage may contain both vitamin d and 25 - oh d3 each in an amount from 30 μg to about 1500 μg , preferably about 75 μg to about 500 μg . a kit may be comprised of one , two , three , four , five , six , seven , eight , nine , ten , eleven , or twelve weekly or monthly dosages . dosage ratios of vitamin d to 25 - oh d3 should range between 50 : 1 to about 1 : 50 , more preferably from about 25 : 1 to about 1 : 25 , and even more preferably from about 6 : 1 to about 1 : 6 . a study of the pharmacokinetics in humans of orally - administered spray - dried formulation of 25 - oh d3 , spray - dried formulation of vitamin d3 , or both was initiated to investigate their physiological interactions . in particular , the shapes of their dose - response curves ( which indicates the concentrations of vitamin d3 and 25 - oh d3 in the circulation over a set time course , not simply the average or maximum concentration achieved ) and the steady - state kinetics were of interest . in respect of the former point , it is important to investigate the change in shape of the dose - response curves when exposure is to both vitamin d3 and 25 - oh d3 . in respect of the latter point , it is also necessary to investigate their steady - state kinetics when dosing is less frequent than daily because this is the preferred regimen for groups that may have low compliance with taking daily supplements ( such as the elderly ). the following non - limiting examples are presented to better illustrate the invention . spray - dried formulation of 25 - oh d3 was provided as a powder . in summary , 25 - oh d3 and dl - α - tocopherol were dissolved in an oil of medium chain triglycerides , then emulsified into an aqueous solution of modified starch , sucrose , and sodium ascorbate . the emulsion was atomized in a spray dryer in the presence of silicon dioxide . the resulting powder was collected when water content ( ldo ) was less than 4 % and sieved through 400 μm . it was packed and sealed in alu - bags , then stored in a dry area below 15 ° c . and used within 12 months of its manufacture . three separate lots were manufactured . in detail , a matrix was produced by mixing for 120 min in a frymix processing unit with an anchor stirrer at 70 ° c . under vacuum and consisting of : an oil phase was prepared by mixing for 35 min in a double - walled vessel with propeller stirrer at 82 ° c . and consisting of : the oil phase was transferred to the matrix in the frymix processing unit and was pre - emulsified with its internal colloid mill ( 60 min , 70 ° c .). the pre - emulsion was circulated through a high - pressure homogenizer ( 20 min ). the emulsion with a viscosity of 60 mpa · s to 90 mpa · s at 70 ° c . was transferred over the high pressure pump to the spray nozzle . as fluidizing agent , silicon dioxide ( sipernat 320 ds ) was fed into the tower . the spraying and drying parameters are listed below . for each of the three lots of 25 - oh d3 , an average of 8 . 4 kg of spray - dried powder with about 0 . 25 % content of 25 - oh d3 was obtained . the other components of the formulation are : 73 . 2 % modified food starch , 17 . 6 % sucrose , 4 . 0 % sodium ascorbate , 3 . 0 % medium chain triglycerides , 1 . 0 % silicon dioxide , and 1 . 0 % dl - α - tocopherol . spray - dried formulation of vitamin d3 was provided as a powder . in summary , vitamin d3 and dl - α - tocopherol were dissolved in an oil of medium chain triglycerides , then emulsified into an aqueous solution of modified starch , sucrose , and sodium ascorbate . the emulsion was atomized in a spray dryer in the presence of silicon dioxide . the resulting powder was collected when water content ( lod ) was less than 4 % and sieved to remove big lumps . it was stored in a dry area below 15 ° c . and used within 12 months of its manufacture . healthy , postmenopausal women ( 50 to 70 years of age ) were recruited using informed consent and screened using the following criteria : serum 25 - hydroxy vitamin d3 between 20 nmol / l and 50 nmol / l , body mass index between 18 kg / m 2 and 27 kg / m 2 , blood pressure less than 146 / 95 mm hg , serum calcium less than 2 . 6 nmol / l , fasting glucose less than 100 mg / dl , no high - intensity exercise more than three times per week , no treatment for hypertension , no use of high - dose vitamin d or calcium supplement or drug affecting bone metabolism ( e . g ., biphosphonate , calcitonin , estrogen receptor modulator , hormone replacement therapy , parathyroid hormone ), and not visiting a “ sunny ” location during the study . subjects were randomly assigned to one of seven treatment groups ( i . e ., daily , weekly , bolus as single dose , and bolus as combination dose ). each group included five subjects . they are followed for four months in zürich , switzerland during the winter . pharmacokinetic characteristics of vitamin d3 and 25 - oh d3 were studied . equimolar quantities of both substances were investigated . the regimen was based on 20 μg / day ( or its equivalent on a weekly basis ) of 25 - oh d3 . for comparative purposes , it was necessary to administer equimolar quantities of either vitamin d3 or 25 - oh d3 . in respect to administration of vitamin d3 , the dose was considered to be sufficient to overcome background variability and provide and efficacious dose to the participants . hard gel capsules , which were packaged in bottles , contained either 20 μg or 140 μg of either spray - dried vitamin d3 or 25 - oh d3 per capsule . each dosage was consumed orally at breakfast . the duration of the study was four months for the “ daily ” and “ weekly ” groups . subjects enrolled in the “ bolus ” group consumed orally a single dosage at the second study visit . plasma concentrations of 25 - oh d3 ( e . g ., peak and steady state ) were determined by obtaining samples from the subjects at various times after the dosage was ingested . for screening purposes and to establish baseline values , a blood sample was obtained prior to enrollment into the study and the clinical laboratory measures vitamin d3 , 25 - oh d3 , calcium , creatinine , albumin , and fasting glucose in the serum . on monday of week 1 of the study , pharmacokinetics of serum vitamin d3 , 25 - oh d3 , and 1 , 25 - dihydroxyvitamin d3 ; serum markers ( i . e ., vitamin d3 , 25 - oh d3 , calcium , creatinine , albumin , pth , got , gpt , alp , triglycerides , hdl , ldl , total cholesterol , balp , and fasting glucose ); and urine markers ( i . e ., calcium , creatinine , and dpd ) were assessed over 24 hours . daily samples for the remaining days of week 1 and monday of week 2 were taken to assess serum vitamin d3 and 25 - oh d3 , serum markers ( i . e ., calcium , creatinine , albumin ), and urine markers ( i . e ., calcium , creatinine ). the assessments continued on monday of weeks 3 , 5 , 7 , 9 , 11 , 13 and 15 . on monday of week 16 , samples were taken to assess pharmacokinetics of serum vitamin d3 , 25 - oh d3 , and 1 , 25 - dihydroxyvitamin d3 ; serum markers ( i . e ., vitamin d3 , 25 - oh d3 , calcium , creatinine , albumin , pth , got , gpt , alp , triglycerides , hdl , ldl , total cholesterol , balp , and fasting glucose ); and urine markers ( i . e ., calcium , creatinine , and dpd ). table 1 shows bone resorption markers deoxypyridinoline ( dpd ) and bone - specific alkaline phosphatase ( bap ) after daily and weekly treatment with 25 - oh d3 ( 20 μg per day ; 140 μg per week , respectively ) and daily and weekly treatment with vitamin d3 ( 20 μg per day ; 140 μg per week , respectively ). treatment duration was 4 months . values are glm ( general linear model ) least square means after 4 months adjusted for baseline bone resorption markers , age and body mass index for 25 - oh d3 and vitamin d3 . table 2 shows the relative change in bone resorption markers deoxypyridinoline ( dpd ) and bone - specific alkaline phosphatase ( bap ) after daily and weekly treatment with 25 - oh d3 ( 20 μg per day ; 140 μg per week , respectively ) compared to daily and weekly treatment with vitamin d3 ( 20 μg per day ; 140 μg per week , respectively ). treatment duration was 4 months . values are glm ( general linear model ) least square means given as % improvement adjusted for baseline bone markers , age and body mass index for 25 - oh d3 versus vitamin d3 are given as % reduction of bone resorption markers after repeated measurement analysis over 13 visits adjusted for baseline bone resorption markers and time for 25 - oh d3 versus vitamin d3 . these data demonstrate that daily or weekly treatment with 25 - oh d3 surprisingly results is much stronger reductions of bone resorption markers compared to consumption of identical dosages of vitamin d3 . after treatment with 25 - oh d3 subjects displayed more pronounced reductions in bone resorption markers compared to before treatment and compared to treatment with vitamin d3 . the reduction of deoxypyridinoline ( dpd ) and bone - specific alkaline phosphatase ( bap ) in subjects treated with 25 - oh d3 versus vitamin d3 was 17 . 0 and 2 . 4 %, respectively , an effect size that is clinically relevant and represents a significant benefit for subjects in all age groups . a reduction of markers for bone resorption such as deoxypyridinoline ( dpd ) and bone - specific alkaline phosphatase ( bap ) indicates that the balance between bone resorption and bone formation is shifted to formation which ultimately results in accretion of bone mass or at least decreased loss of bone mass . in conclusion , treatment with 25 - oh d3 surprisingly resulted in a very effective reduction of bone resorption markers compared to vitamin d3 indicating that net bone formation is improved following treatment with 25 - oh d3 . as shown above , there was a synergistic increase in the plasma 25 - oh d response after a combined administration of 140 μg 25 - oh d3 + 140 μg vitamin d3 . the effect was especially pronounced during the first 6 hours . furthermore , a combined administration produced sustained increase in plasma 25 - oh d levels by at least 30 nmol / l from 2 - 206 hours ( i . e until 8 . 5 days , or over 1 week ). after administration of 140 μg 25 - oh d3 , an increase in plasma 25 - oh d levels by at least 30 nmol / l was observed between 4 - 49 hours only , whereas no increase of that magnitude was observed after administration of 140 μg vitamin d3 alone . therefore , a combined administration of 140 μg 25 - oh d3 + 140 μg vitamin d3 provides two significant advantages : it results in a rapid and synergistic plasma response of 25 - oh d and it leads to an unexpectedly pronounced and long plateau of plasma 25 - oh d levels . these are especially important goals of treatment of vitamin d deficiency ; fast correction of suboptimal vitamin d status and a long and stable plasma concentration to ensure sufficient supply of all vitamin d dependent tissues . treatment with 25 - oh d3 reduces bone resorption makers more effectively compared to an equal dosage of vitamin d3 . this results in a more pronounced shift of the balance between bone resorption and bone formation towards bone formation and , therefore , to improved bone health . due to the synergistic increase in plasma 25 - oh d levels after combined administration of 25 - oh d3 and vitamin d3 bone formation is accelerated even further which results in stronger benefits for bone health .
we disclose the combined use of vitamin d and 25 - oh d3 to treat and / or prevent osteoporosis . one or more bisphosphonate compounds to inhibit bone resorption may also be used . forms and dosages of a pharmaceutical composition , as well as processes for manufacturing medicaments , are also disclosed .